The emergence of new GLP-1 RAs for the treatment of type 2 diabetes and obesity holds promise for those with CKD, and reduces the risk of kidney disease progression in patients with type 2 diabetes and CKD.15 This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.